Omalizumab for chronic urticaria in Latin America

Show other versions (1)

Abstract Background Chronic urticaria (CU) is defined as the spontaneous appearance of wheals, with or without angioedema, persisting for ≥6 weeks. Chronic Spontaneous Urticaria (CSU) is a type of CU which affects 0.5–1 % of the global population, but it represents a high burden to patients. In rece...

Full description

Bibliographic Details
Published in:	World Allergy Organization Journal
Main Authors:	Paul Wilches, Paola Wilches, Juan Carlos Calderon, Annia Cherrez, Ivan Cherrez Ojeda
Format:	Article
Language:	English
Published:	Elsevier 2016-11-01
Subjects:	Omalizumab Chronic urticaria Anti-IgE Real life study Latin America
Online Access:	http://link.springer.com/article/10.1186/s40413-016-0127-y

Similar Items

Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature
by: Ilya Ivyanskiy, et al.
Published: (2012-01-01)

Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience
by: Joanna Dawicka, et al.
Published: (2016-02-01)

Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga
by: Ana G. Lopes, et al.
Published: (2022-10-01)

Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
by: Davide Stefano Sardina, et al.
Published: (2021-11-01)

Predicting responses to omalizumab in antihistamine-refractory chronic urticaria: A real-world longitudinal study
by: Hyun-Young Lee, PhD, et al.
Published: (2024-05-01)

Omalizumab withdrawal outcomes in chronic spontaneous urticaria are linked with baseline IgE and eosinophil levels
by: Ramit Maoz-Segal, MD, et al.
Published: (2024-05-01)

Omalizumab for the management of refractory chronic spontaneous urticaria
by: P C Kathuria, et al.
Published: (2022-01-01)

Omalizumab for chronic urticaria in Latin America
by: Paul Wilches, et al.
Published: (2016-01-01)

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
by: Thomas B. Casale, et al.
Published: (2023-09-01)

Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador
by: A. Cherrez, et al.
Published: (2017-05-01)

Type I and type IIb autoimmune chronic spontaneous urticaria: Using common clinical tools for endotyping patients with CSU
by: Juliana A. Sella, MD, PhD, et al.
Published: (2023-11-01)

Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies
by: Olguța Anca Orzan, et al.
Published: (2022-06-01)

Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency
by: Pasquale Comberiati, et al.
Published: (2019-07-01)

The Potential Role of Basophils in Urticaria
by: Riko Takimoto-Ito, et al.
Published: (2022-05-01)

Sex, Allergic Diseases and Omalizumab
by: Maria Maddalena Sirufo, et al.
Published: (2022-01-01)

Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn’s Disease
by: Simona Barni, et al.
Published: (2021-03-01)

Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response
by: Ramón Gimeno, et al.
Published: (2023-03-01)

The use of an urticaria control test for the evaluation of omalizumab treatment response in patients diagnosed with chronic urticaria
by: Burhan Engin, et al.
Published: (2020-12-01)

Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases
by: Anthony F. LaCava, et al.
Published: (2023-08-01)

Solar urticaria, a disease with many dark sides: is omalizumab the right therapeutic response? Reflections from a clinical case report
by: De Martinis Massimo, et al.
Published: (2019-06-01)

Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab?
by: Thomas B. Casale, MD, et al.
Published: (2024-08-01)

Retrospective analysis of the treatment of 61 cases of chronic spontaneous urticaria with omalizumab
by: Shanshan OU, et al.
Published: (2023-04-01)

Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
by: Ragıp Ertaş, et al.
Published: (2016-01-01)

Omalizumab's efficacy and safety against chronic spontaneous urticaria
by: Öner Özdemir
Published: (2023-08-01)

The prevalence of patients suffering from chronic spontaneous urticaria, in whom omalizumab cannot be stopped even after six years
by: V. Schichter-Konfino, et al.
Published: (2024-10-01)

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
by: Kiran Godse, et al.
Published: (2016-01-01)

Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI
by: Agnes Yang, BS, et al.
Published: (2025-05-01)

Progress in the application of omalizumab in the treatment of chronic inducible urticaria
by: CHEN Ziyan, et al.
Published: (2024-12-01)

Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients
by: Cristina López, et al.
Published: (2024-08-01)

Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria
by: Eli Magen
Published: (2019-07-01)

IgE and high‐affinity IgE receptor in chronic inducible urticaria, pathogenic, and management relevance
by: Ana M. Giménez‐Arnau, et al.
Published: (2022-02-01)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
by: Shuang-Lu Liao, et al.
Published: (2021-03-01)

Cost‐of‐illness analysis of chronic urticaria clinical management in five countries of Latin America
by: Jorge Sánchez, et al.
Published: (2025-01-01)

The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment
by: Gokhan Aytekin, et al.
Published: (2021-09-01)

Utilidad clínica del omalizumab en urticaria crónica inducible
by: Ricardo Cardona
Published: (2018-06-01)

Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study
by: Michihiro Hide, et al.
Published: (2023-04-01)

Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
by: Emek Kocatürk, et al.
Published: (2022-09-01)

Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?
by: Petek Üstün, et al.
Published: (2025-07-01)

COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports
by: Angelo Massimiliano D'Erme, et al.
Published: (2023-08-01)

Cold urticaria with risk of anaphylaxis treated with omalizumab: a case report
by: Tonatiuh Ramses Bedolla-Pulido, et al.
Published: (2021-02-01)